ADM Tronics Reports Fiscal Year 2025

Rhea-AI Summary

ADM Tronics (OTCQB:ADMT) reported improved financial results for fiscal year 2025. The company achieved an 8% revenue increase to $3,197,110, driven by growth in engineering services ($232,469) and electronics manufacturing. Gross profit margin improved to 44% from 38% year-over-year.

Operating losses decreased significantly by 89% to $94,024, while net loss improved by 86% to $123,056. The company focused R&D efforts on developing a medical version of Sonotron®, a non-invasive pain treatment technology using pulsed radio frequency, and launched Vet-Sonotron® for veterinary applications.

Positive

• Revenue increased 8% to $3.2M year-over-year
• Operating loss reduced by 89% compared to previous year
• Net loss improved by 86% to $123,056
• Gross profit margin increased to 44% from 38%
• Operating expenses decreased by 23% to $1.49M

Negative

• Company still operating at a loss ($94,024 operating loss)
• Chemical segment revenue declined by $14,309
• FDA approval still pending for human medical version of Sonotron

NORTHVALE, NJ / ACCESS Newswire / July 14, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies, products, and proprietary medical devices, announces results for fiscal year ended March 31, 2025.

For the fiscal year ended March 31, 2025, loss from operations was approximately 89% less than the previous fiscal year. Revenues for fiscal year ended March 31, 2025 increased approximately 8% as compared to the previous fiscal year. The increase in revenues was due to an increase of $232,469 in engineering services revenue and an increase of $13,544 in electronics manufacturing segment revenue, offset by a reduction of $14,309 in chemical segment revenue.

Revenues for the fiscal year ended March 31, 2025, were $3,197,110 compared to $2,965,406 for the previous fiscal year, an increase of approximately 8%. Gross profit for the March 31, 2025 fiscal year was $1,395,660 or approximately 44% as compared to $1,116,422 or approximately 38% for the previous fiscal year. Operating expenses for the fiscal year ended March 31, 2025 were $1,489,684, a decrease of approximately 23% from operating expenses of $1,936,318 for the previous fiscal year. Loss from operations of $94,024 for the fiscal year ended March 31, 2025 was 89% lower than loss from operations of $819,896 for the previous fiscal year. Net loss for the fiscal year ended March 31, 2025 was $123,056, as compared to net loss of $877,222 for the previous fiscal year, a reduction of 86%.

During the fiscal year ended March 31, 2025, ADMT devoted substantial research and development resources to development of the medical version of the Sonotron^® for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet. This non-invasive therapy technology utilizes pulsed radio frequency output for the treatment of chronic and acute musculoskeletal pain conditions such as osteoarthritis, tendonitis, and other conditions and diseases. The company plans on pursuing a 510(k) submission to the FDA when the development of the human medical version is completed. The Company commercially introduced the Vet-Sonotron^®, a professional veterinary version of this technology for treatment of animals, and is seeking national or regional distributors for sales and marketing to the small animal and equine veterinary markets. See videos:

https://youtu.be/coQUgO7Gssw?si=I9cUOsJ-AnGDyBhO

https://youtu.be/opa-THES9qw?si=LfG8kExhN-EpVJg1

https://youtube.com/shorts/wGVcyaHnd60?si=Y34wwAk565RSnCcS

Complete financial results are available in the Company's Annual Report on Form 10K at www.sec.gov.

Financial Highlights

		Fiscal Year Ended				Fiscal Year Ended
		March 31, 2025				March 31, 2024
Net revenues		$	3,197,110			$	2,965,406
Cost of sales		$	1,801,450			$	1,848,984
Gross Profit		$	1,395,660			$	1,116,422
Total operating expenses		$	1,489,684			$	1,936,318
Loss from operations		$	(94,024	)		$	(819,896	)
Total other income (expense)		$	(27,532	)		$	(57,326	)
Loss before provision for taxes		$	(121,556	)		$	(877,222	)
Total benefit (provision) from income taxes		$	1,500				-
Net loss		$	(123,056	)		$	(877,222	)
Basic and diluted earnings (loss) per common share:		$	(0.00	)		$	(0.01	)
Weighted average shares of common stock outstanding - basic and diluted			67,588,492				67,588,492

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Medical Devices; Medical Device Design, Engineering, Regulatory and Manufacturing Services; and Eco-Friendly, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered and ISO 13485 Certified medical device and manufacturing operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure for research, development and commercialization of diversified technologies.

ADMT welcomes inquiries for its electronics and medical device development and manufacturing services at www.admtronics.com.

To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/

Sonotron^® - a registered trademark of ADM Tronics Unlimited, Inc.

Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's SEC filings, news releases and other communications. The Company assumes no obligation to update information contained in this news release.

Contact:

Andre DiMino
andre@admtronics.com

SOURCE: ADM Tronics Unlimited Inc.

View the original press release on ACCESS Newswire

FAQ

What were ADMT's key financial results for fiscal year 2025?

ADMT reported revenue of $3.2M (up 8%), gross profit margin of 44%, and reduced its operating loss by 89% to $94,024.

How much did ADMT's revenue grow in FY 2025?

ADMT's revenue grew by 8% to $3,197,110, primarily driven by increases in engineering services ($232,469) and electronics manufacturing.

What is the status of ADMT's Sonotron technology development?

ADMT is developing a medical version of Sonotron for human pain treatment and plans to pursue FDA 510(k) submission. They have already launched Vet-Sonotron for veterinary applications.

How did ADMT's operating expenses change in FY 2025?

ADMT's operating expenses decreased by 23% to $1,489,684 compared to $1,936,318 in the previous fiscal year.

What was ADMT's net loss for fiscal year 2025?

ADMT reported a net loss of $123,056 for FY 2025, an 86% improvement from the previous year's net loss of $877,222.